Correlation of deviation from intended cisplatin (CDDP) dose intensity with outcome in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) receiving concurrent chemoradiation (CRT)

被引：0
|
作者：
Liu, C. S.
Elser, C.
Huang, S.
Pond, G. R.
O'Sullivan, B.
Chen, E. X.
Waldron, J. N.
Goldstein, D.
Siu, L. L.
Kim, J.
机构：
[1] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada
[2] Everest Clin Res Serv, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.6052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6052
引用
收藏
页数：1
相关论文
共 50 条
  • [1] DELIVERY OF LESS THAN INTENDED CISPLATIN (COOP) DOSE INTENSITY IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (LA-HNSCC) RECEIVING CONCURRENT CHEMORADIATION (CRT) CORRELATES WITH POORER OUTCOME
    Liu, C.
    Elser, C.
    Huang, S.
    Pond, G. R.
    O'Sullivan, B.
    Chen, E. X.
    Waldron, J. N.
    Bayley, A. J.
    Cummings, B. J.
    Dawson, L. A.
    Ringash, J.
    Goldstein, D.
    Siu, L.
    Kim, J.
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S13 - S13
  • [2] Factors associated with hospitalization in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) treated with definitive chemoradiation (CRT).
    Park, Soo J.
    Parikh, Mili
    Harrington, Joanne
    Heppner, Pia
    McCarthy, Kelly
    Crandall, Bailey
    Wong-Sefidan, Ida
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Cisplatin dose intensity correlates with outcome in patients with locally advanced head and neck squamous cell carcinoma receiving concurrent cisplatin based chemoradiation: a multi-institutional experience
    Granata, R.
    Pond, G.
    Kim, J.
    Siu, L. L.
    Olmi, P.
    Orlandi, E.
    Bossi, P.
    Locati, L. D.
    Licitra, L.
    EJC SUPPLEMENTS, 2009, 7 (02): : 472 - 472
  • [4] CISPLATIN DOSE INTENSITY CORRELATES WITH OUTCOME IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA RECEIVING CONCURRENT CISPLATIN BASED CHEMORADIATION: A MULTI-INSTITUTIONAL EXPERIENCE
    Granata, R.
    Pond, G.
    Kim, J.
    Siu, L. L.
    Olmi, P.
    Orlandi, E.
    Bossi, P.
    Locati, L.
    Bergamini, C.
    Calderone, R. G.
    Potepan, P.
    Quattrone, P.
    Licitra, L.
    ANNALS OF ONCOLOGY, 2009, 20
  • [5] Pembrolizumab and radiotherapy for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) with contraindication to cisplatin therapy
    Sheth, S.
    Bauman, J. R.
    Deal, A.
    Chera, B.
    Shen, C.
    Galloway, T.
    Hackman, T.
    Blumberg, J.
    Yarbrough, W.
    Weissler, M.
    Hilliard, C.
    Mehra, R.
    Grilley-Olson, J.
    Weiss, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Response of chemoradiation therapy after induction chemotherapy failure in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
    Lim, Yoojoo
    Keam, Bhumsuk
    Koh, Youngil
    Lee, Kyung-Hun
    Kim, Tae Min
    Lee, Se-Hoon
    Hah, Jeong-Hun
    Kwon, Tack-Kyun
    Kim, Dong-Wan
    Wu, Hong-Gyun
    Sung, Myung-Whun
    Heo, Dae Seog
    Kim, Kwang Hyun
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Predictors of toxicity to concurrent chemoradiation (CRT) in patients (pts) with locally advanced head and neck squamous cell cancer (HNSCC)
    Yelamanchili, R.
    Hotte, S.
    Julian, J.
    Wright, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] KEYNOTE-412: Phase 3 trial of pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
    Yen, C-J.
    Machiels, J-P.
    Licitra, L.
    Rischin, D.
    Waldron, J.
    Burtness, B.
    Gregoire, V.
    Tao, Y.
    Yorio, J.
    Aksoy, S.
    Ikeda, S.
    Hong, R-L.
    Ge, J. Y.
    Brown, H.
    Bidadi, B.
    Siu, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Phase 3 study of Pembrolizumab plus Chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC): KEYNOTE-412
    Machiels, Jean-Pascal
    Yen, Chia-Jui
    Licitra, Lisa
    Rischin, Danny
    Waldron, John
    Burtness, Barbara
    Gregoire, Vincent
    Agarwala, Sanjiv
    Tao, Yun Gan
    Yorio, Jeffrey
    Aksoy, Sercan
    Ikeda, Sadakatsu
    Hong, Ruey-Long
    Ge, Joy Yang
    Brown, Holly
    Bidadi, Behzad
    Siu, Lillian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [10] Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
    Machiels, J-P.
    Yen, C-J.
    Licitra, L.
    Rischin, D.
    Waldron, J.
    Burtness, B.
    Gregoire, V.
    Tao, Y. G.
    Yorio, J.
    Aksoy, S.
    Ikeda, S.
    Hong, R-L.
    Ge, J. Y.
    Brown, H.
    Bidadi, B.
    Siu, L.
    ANNALS OF ONCOLOGY, 2017, 28
12345